ZYDUS PHARMACEUTICALS (USA) INC. - NEW AWARD FOR DPP-4 SITAGLIPTIN WITH ZYDUS PHARMACEUTICALS (USA)INC. PERIOD OF PERFORMANCE IS 5/18/2024 - 5/17/2025 WITH FOUR ONE-YEAR OPTION PERIODS.
Key Details
Description
NEW AWARD FOR DPP-4 SITAGLIPTIN WITH ZYDUS PHARMACEUTICALS (USA)INC. PERIOD OF PERFORMANCE IS 5/18/2024 - 5/17/2025 WITH FOUR ONE-YEAR OPTION PERIODS.
Context & Analysis
On Dec 8, 2025, Department of Veterans Affairs to ZYDUS PHARMACEUTICALS (USA) INC. for new award for dpp-4 sitagliptin with zydus pharmaceuticals (usa)inc. period of performance is 5/18/2024 - 5/17/2025 with four one-year option periods.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.